Streetbeat News

Products Services

NRIX

Nurix Therapeutics shares are trading higher following the announcement of positive results from its ongoing clinical trial of NX-5948 in patients with relapsed refractory chronic lymphocytic leukemia.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 11:32 am

CYTK

Cytokinetics has initiated a Phase 1 study to evaluate the pharmacokinetics, safety, and tolerability of Aficamten in healthy Japanese and Caucasian participants.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 11:32 am

BNTX

The FDA has placed a partial clinical hold on the Phase 1 trial of BNT326/YL202, a treatment for advanced or metastatic EGFR-mutated non-small cell lung cancer or HR+/HER2-negative breast cancer, due to safety concerns. This affects the enrollment of new patients in the U.S. BioNTech's partner, Medilink Therapeutics, must address these concerns by reviewing clinical and safety data and providing additional information to the FDA.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 11:27 am

SON

Sonoco announced a price increase of at least 6% for all converted paperboard products, effective July 10th, 2024. This includes tubes, cores, cones, and protective packaging.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 11:07 am

TM

Toyota has partnered with energy utility Pepco to research vehicle-to-grid (V2G) technology in Maryland. This collaboration aims to explore how electric vehicles can support the energy grid by providing stored energy during peak demand times.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 11:06 am

AEVA

Digitale Schiene Deutschland has selected Aeva's 4D LiDAR technology for its automated train project, marking a significant milestone for Aeva in the transportation sector.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 11:06 am

CBUS

Cibus has confirmed successful edits in canola for its initial nutrient use efficiency trait. The newly edited plants will now undergo testing in controlled environments.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 11:06 am

MRNS

Marinus Pharmaceuticals announced mixed results from its Phase 3 RAISE trial of intravenous ganaxolone for refractory status epilepticus. The trial met the first co-primary endpoint but failed the second. The company will focus on its ZTALMY franchise and expects Phase 3 TrustTSC topline data in Q4 2024. Marinus projects a cash runway into Q2 2025 due to cost reduction plans and recent financing.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 11:03 am

CSIQ

Canadian Solar has initiated its first Feed-In Premium (FIP) projects in Japan and signed a Power Purchase Agreement with Toyota Tsusho. The projects include a 1.2 MWp project in Tsukuba City and a 1.9 MWp project in Daisen Town, both powered by CS7N-660W bifacial modules. Initially awarded a feed-in tariff (FIT), the projects were switched to FIP to meet the rising demand for renewable energy, generating additional revenue through Non-Fossil Certificates (NFCs).

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 11:03 am

PSNY

Polestar is accelerating its geographic expansion and plans to enter seven new markets during 2025. The company is widening its retail footprint with existing and new partners, and has added experienced senior leadership in key markets.

Portfolio Pulse from Benzinga Newsdesk

June 17, 2024 | 11:03 am